The theme of the December 2012 SMR meeting is 'Recent Disclosures of Clinical Candidates' with an international line-up of speakers presenting on the discovery and clinical development of agents that are progressing through clinical trials. The programme includes a variety of mechanistic approaches for therapeutics, including small molecules and mirror-image oligonucleotides. This meeting also includes the presentation of the 2012 SMR Award for Drug Discovery. The SMR committee are delighted to announce that the winner of this award is Vertex, for the discovery of Telaprevir. Peter Mueller (Executive Vice President, Global Research and Development, and Chief Scientific Officer) of Vertex will accept the award and give the award lecture on the discovery and development of Telaprevir.
About Us | Advertise On This Site | Cookies | Contact Us | Home | Support | Terms & Conditions